Manulife (Manufacturers Life Insurance)
OCUL icon

Manulife (Manufacturers Life Insurance)’s Ocular Therapeutix OCUL Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.93M Buy
227,808
+135,160
+146% +$1.29M ﹤0.01% 1510
2025
Q4 		$1.12M Buy
92,648
+21,015
+29% +$255K ﹤0.01% 1789
2025
Q3 		$837K Sell
71,633
-985
-1% -$11.8K ﹤0.01% 1950
2025
Q2 		$674K Buy
72,618
+1,314
+2% +$10.3K ﹤0.01% 2015
2025
Q1 		$523K Sell
71,304
-56,499
-44% -$434K ﹤0.01% 2122
2024
Q4 		$1.09M Sell
127,803
-2,399
-2% -$23.4K ﹤0.01% 1871
2024
Q3 		$1.13M Buy
130,202
+13,238
+11% +$109K ﹤0.01% 1861
2024
Q2 		$800K Buy
116,964
+44,524
+61% +$275K ﹤0.01% 1968
2024
Q1 		$659K Buy
72,440
+40,703
+128% +$289K ﹤0.01% 2074
2023
Q4 		$142K Hold
31,737
– – ﹤0.01% 2726
2023
Q3 		$99.7K Hold
31,737
– – ﹤0.01% 2810
2023
Q2 		$164K Buy
31,737
+199
+0.6% +$1.18K ﹤0.01% 2678
2023
Q1 		$166K Hold
31,538
– – ﹤0.01% 2627
2022
Q4 		$88.6K Sell
31,538
-373
-1% -$1.24K ﹤0.01% 2822
2022
Q3 		$132K Sell
31,911
-1,077
-3% -$5.42K ﹤0.01% 2727
2022
Q2 		$133K Buy
32,988
+32
+0.1% +$121 ﹤0.01% 2828
2022
Q1 		$163K Sell
32,956
-8,697
-21% -$48.2K ﹤0.01% 2842
2021
Q4 		$290 Buy
41,653
+881
+2% +$6.84K ﹤0.01% 2621
2021
Q3 		$408K Sell
40,772
-2,968
-7% -$33.3K ﹤0.01% 2438
2021
Q2 		$620K Buy
43,740
+2,793
+7% +$42.5K ﹤0.01% 2280
2021
Q1 		$672K Buy
40,947
+128
+0.3% +$2.46K ﹤0.01% 2112
2020
Q4 		$845K Buy
40,819
+6,298
+18% +$93.5K ﹤0.01% 1917
2020
Q3 		$263K Buy
34,521
+2,944
+9% +$24.4K ﹤0.01% 2393
2020
Q2 		$261K Buy
31,577
+2,969
+10% +$19.7K ﹤0.01% 2343
2020
Q1 		$142K Buy
28,608
+1,173
+4% +$5.79K ﹤0.01% 2466
2019
Q4 		$108K Buy
27,435
+110
+0.4% +$382 ﹤0.01% 2783
2019
Q3 		$88K Buy
27,325
+40
+0.1% +$179 ﹤0.01% 2851
2019
Q2 		$120K Buy
27,285
+766
+3% +$2.84K ﹤0.01% 2853
2019
Q1 		$105K Buy
26,519
+14,667
+124% +$59K ﹤0.01% 2572
2018
Q4 		$47K Sell
11,852
-14,606
-55% -$80.5K ﹤0.01% 2486
2018
Q3 		$182K Sell
26,458
-1,301
-5% -$8.16K ﹤0.01% 2791
2018
Q2 		$187K Buy
27,759
+3,636
+15% +$25K ﹤0.01% 3170
2018
Q1 		$157K Buy
24,123
+18,492
+328% +$104K ﹤0.01% 3203
2017
Q4 		$25K Buy
5,631
+4,283
+318% +$21.9K ﹤0.01% 3738
2017
Q3 		$8K Sell
1,348
-17,391
-93% -$112K ﹤0.01% 3907
2017
Q2 		$174K Buy
18,739
+3,650
+24% +$35.3K ﹤0.01% 3125
2017
Q1 		$140K Buy
15,089
+2,037
+16% +$17K ﹤0.01% 3033
2016
Q4 		$109K Buy
13,052
+7,197
+123% +$55.8K ﹤0.01% 3187
2016
Q3 		$40K Buy
5,855
+5,097
+672% +$31.1K ﹤0.01% 3437
2016
Q2 		$4K Sell
758
-10,425
-93% -$103K ﹤0.01% 3866
2016
Q1 		$105K Buy
11,183
+913
+9% +$6.92K ﹤0.01% 3023
2015
Q4 		$96 Hold
10,270
– – ﹤0.01% 3103
2015
Q3 		$144 Buy
10,270
+1,221
+13% +$24.5K ﹤0.01% 2918
2015
Q2 		$190 Buy
9,049
+4,397
+95% +$109K ﹤0.01% 2891
2015
Q1 		$195 Buy
4,652
+3,045
+189% +$100K ﹤0.01% 2754
2014
Q4 		$38 Buy
+1,607
New +$27K ﹤0.01% 3289

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s OCUL Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) increased its Ocular Therapeutix (OCUL) stake by 146% in Q1 2026, buying an estimated $1.29M and bringing the position to 227,808 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #1510.

Manulife (Manufacturers Life Insurance) first reported a position in OCUL in Q4 2014 and has held it in 46 quarters since. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 227,808 shares of Ocular Therapeutix worth $1.93M as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) bought 135,160 Ocular Therapeutix shares in Q1 2026, an estimated $1.29M.
  • Ocular Therapeutix made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #1510 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Ocular Therapeutix in Q4 2014 and has held it in 46 quarters since.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.